Atriva Therapeutics GmbH

General information
Atriva Therapeutics GmbH
Am Klopferspitz 19
82152 Planegg, Bavaria

Contact person: Christian M. Pangratz, Chief Executive Officer
Company main phone: +49 (69) 999916210
Year founded:2015
Source of foundation:Spin-off from university
Name of foundation source:Universities of Giessen, Münster and Tübingen
Corporate description / mission:
Atriva Therapeutics is a biopharmaceutical company developing host-cell-targeting antiviral and immunomodulatory therapies. The company aims to develop novel, highly efficacious, and safe therapies for the treatment of severe diseases caused by RNA viruses with a high unmet medical need and huge cost burden to healthcare systems around the world such as influenza, respiratory syncytial virus infections, dengue fever, and hantavirus infections. Atriva Therapeutics' lead product zapnometinib is a novel, host-cell-targeting, orally available small-molecule drug inhibiting viral replication and rebalancing the body's immune response. The company will primarily focus resources on the development of zapnometinib for the treatment of patients hospitalized with severe influenza infections.
State of ownership: Private / independent
Headquarters: HQ: Yes
Remarks on ownership / listings
Ownership: Boutique Venture Funds, HTGF, Family Offices, founders and management
  • Biotechnology - Therapeutics and Diagnostics
  • Anti-infectives
  • Small molecules
Primary therapeutic areas:
  • Infectious and parasitic diseases / infectiology / parasitology
  • Respiratory / pulmonology
Business model:
  • R&D
Customer segments:
  • Hospitals
  • Large biotech & big pharma
  • Indirect (independent dealer)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:1
Phase II:1
Description of products:
Special IP situation:
The company owns eleven broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041
Technology used:
Atriva product platform is based on MEK kinase inhibitors focusing on severe viral infections and applicable for use with high-risk COVID-19 and influenza patients.